Novavax to initiate phase 2 influenza CIC trial by end 2022

In investor presentation slides, Novavax indicated that the company expects to initiate a Phase 2 influenza and COVID-19-Influenza Combination, or CIC, dose confirmation trial by the end of 2022 with data by mid-year and has an ongoing development plan to support readiness for a Phase 3 influenza efficacy trial in 2023. Novavax sees filing for a U.S. BLA in 2023, the slides stated. See the top stocks recommended by analysts >>

Read More on NVAX:

• Largest borrow rate increases among liquid names
• Novavax call buyer realizes 60% same-day gains
• Unusually active option classes on open December 16th
• Novavax 6.5M share Secondary priced at $10.00
• Novavax put volume heavy and directionally bearish